Escuela de Ciencias del Movimiento Humano y Calidad de Vida
Universidad Nacional, Costa Rica
e-ISSN: 1659-097X
Vol. 23(1), enero-junio, 2026
revistamhsalud@una.ac.cr
Licencia: By NC ND 3.0 Internacional

Doi: https://doi.org/10.15359/mhs.23-1.20144

Cannabidiol’s effectiveness in post-exercise recovery: an integrated systematic review

Análisis de la efectividad del cannabidiol en la recuperación posentrenamiento: una revisión sistemática integradora

Análise da eficácia da canabidiol na recuperação pós-exercício: uma revisão sistemática integrada

Carmen E. Villalobos-González1, Carlos D. Gómez-Carmona2, Braulio Sánchez-Ureña3, Christian Azofeifa-Mora4 & Daniel Rojas-Valverde5

INTRODUCTION

Nowadays, recovery between physical efforts is essential to achieve optimal performance in sports. The increase in the number, frequency, and intensity of competitions has resulted in relatively little time between efforts (Rojas-Valverde et al., 2018), which increases the relevance of planning and implementing effective and accessible recovery strategies (Martínez-Guardado et al., 2020). Physical exertion causes a series of structural and functional alterations that must be controlled, monitored, and counteracted to achieve a rapid return to homeostasis (Ament & Verkerke, 2009). In this sense, depending on the exercise dose, myositis occurs by releasing cytokines (e.g., IL-1, IL-6, TNFα) that trigger inflammatory responses (Metsios et al., 2020) and lead to an effective but relatively slow recovery process. Sports practice can also cause drowsiness, swelling, pain, and weakness for hours or even days (Kreher & Schwartz, 2012). So, these aspects can be largely mitigated with the use of certain recovery measures.

Thanks to scientific and technological advances, the level of performance among elite athletes is very similar, which suggests the need to seek new alternatives to improve performance (Haugen et al., 2019). For recovery effects to achieve optimal performance different ergogenic supplements have been used as dietary supplements (Thomas et al., 2016), antioxidants (Merry & Ristow, 2016), and more recently, organic foods such as ginseng and beetroot (Rojas-Valverde, Montoya-Rodríguez, et al., 2020). One of these proposed new aids is cannabidiol (CBD), a phytocannabinoid grouped among the cannabinoids found in the cannabis sativa plant and also obtained from hemp (Campos et al., 2012).

CBD can be administered in the form of oral solutions, oral capsules, buccal aerosol, and drops, among other presentations, and the dose can vary depending on the desired effect (Lim et al., 2020). Unlike Δ9-tetrahydrocannabinol (THC) is one of the compounds in the cannabis sativa plant, CBD lacks psychotomimetic and psychotropic effects, and there is no evidence of dependence or abuse, and it has a fairly favorable safety and tolerability profile (WHO, 2017). Although somnolence, diarrhea, and an variances on body temperature are among the reported side effects, these are mild and infrequent (Stout & Cimino, 2014). The common concentration of CBD in hemp oils is 12-18% (often higher due to enrichment procedures) (VanDolah et al., 2019); CBD has been administered for medical purposes at doses of 1-50 mg/kg/d (Millar et al., 2019), 200-300 mg/d for six months (Cunha et al., 1980) or 1200-1500 mg/d for four weeks (Zuardi et al., 2010) without significant adverse effects.

In all international sports leagues and organizations, tetrahydrocannabinol (THC) and its metabolites, such as 11-COOH-THC, are prohibited both in and out of competition, with an acceptable threshold of 11-COOH-THC in urine ranging from >15 to 150 ng/ml (Docter et al., 2020). However, isolated cannabidiol (CBD) is not included in the World Anti-Doping Agency’s (WADA) Prohibited List, and it was recently removed from the list (Docter et al., 2020). This reflects a growing social acceptance of CBD and cannabis use for recreational and medicinal purposes, although not all of its biological effects are fully understood (Nichols & Kaplan, 2019). Nevertheless, it is important to note that CBD products may contain traces of THC, so athletes should be cautious when consuming these products to avoid potential anti-doping rule violations (Huestis et al., 2019). In this regard, a recent review on cannabis use in sports suggested that 25% of athletes reported having consumed cannabis in the last 12 months (Docter et al., 2020).

Preclinical and clinical evidence suggests that CBD could provide a positive effect on the treatment of chronic pain, spasticity, and sleep quality (Whiting et al., 2015), and has a potential role in managing mood disorders (Pinto et al., 2020). CBD intake has presented multiple benefits at the immune level, including anti-inflammatory and immunosuppressive effects (Nichols & Kaplan, 2019), both crucial for the recovery of sports injuries and the effects of fatigue caused by the daily physical load that athletes are exposed to (Higgins et al., 2017; Rojas-Valverde, Sánchez-Ureña, et al., 2020). The supposed effects of CBD include, among others, analgesic, antioxidant, anxiolytic, anti-inflammatory, cytotoxic, and anticonvulsant, which are mediated by signaling mechanisms that include cannabinoid receptors, protein-coupled receptors, and serotonin receptors (McPartland et al., 2015).

The mechanism of action of CBD in the body could be explained by the endocannabinoid system, among other body systems that participate in it. This endocannabinoid system participates globally in maintaining homeostasis in the human body and is involved in a variety of regulatory functions such as chronic inflammation and regulation of immune system (VanDolah et al., 2019). The body has its own endogenous cannabinoids and there are strong hypotheses that endocannabinoids could mediate some central and peripheral effects of exercise (Carek et al., 2011). Previous research indicated that endocannabinoids could have an influence on skeletal muscle, adipose tissue, liver, immune system and redox state (Tantimonaco et al., 2014), increasing anti-inflammatory and immunosuppressive responses (Tantimonaco et al., 2014), reducing pain (Cuñetti et al., 2018) and improving sleep and anxiety when consuming CBD (Shannon et al., 2019).

The evidence regarding the use of cannabinoids and CBD in sports is relatively scarce due to a gap in research that lasted for decades that led to a lack of research, reducing the potential benefits of CBD (Burstein, 2015). With the recent legal opening for the medicinal prescription of cannabinoids, as well as an allocation for recreational use with greater popular acceptance, studies have begun to emerge. Although the publication rate on CBD worldwide is relatively low due to some administrative processes regarding the local pharmaceutical institution (Zarrabi et al., 2020), scientists’ interest has increased significantly, implying the need to direct efforts based on the evidence gathered to date.

In sports, recently published narrative reviews on the effect of cannabidiol and its relationship with performance (McCartney et al., 2020) and recovery (Rojas-Valverde, 2021) suggest that CBD possesses anti-inflammatory, neuroprotective, and analgesic effects, and also promotes the healing of traumatic skeletal injuries. Additionally, early-stage clinical studies suggest that CBD may have anxiolytic effects, and some evidence points to an improvement in sleep (McCartney et al., 2020; Rojas-Valverde, 2021). Based on this evidence, and understanding the need to orient future research on CBD and sports recovery, this systematic review aims to: a) systematize the first and second-level scientific evidence related to the study of CBD, b) associate the biomedical properties attributed to CBD with those required for optimal fatigue recovery, and c) recommend a future research agenda related to the role of CBD in recovery. This way, a deeper understanding of the physiological cascade caused by CBD consumption and its potential role in sports recovery can be achieved.

METHODS

Study Design

This study followed an integrative systematic review methodology to synthesize and critically analyze the diverse literature related to the use of cannabidiol (CBD) in sports recovery following the Preferred Reporting Guidelines for Systematic Reviews and Meta-Analysis (PRISMA) (Page et al., 2021). Integrative systematic reviews facilitate the combination and synthesis of different types of evidence, including empirical studies, theoretical literature, and methodological contributions (Whittemore & Knafl, 2005). The key feature of this approach is the possibility of incorporating a wide range of relevant data to build a comprehensive understanding of the topic (Toronto & Remington, 2020).

This integrative systematic methodology was consider appropriate given the emergent and multidisciplinary nature of the research topic, which spans domains such as sports science, exercise physiology, pharmacology, and medicine (Souza et al., 2010). The comprehensive and rigorous synthesis of diverse evidence, including both empirical and non-empirical sources, aligns with the overarching purpose of providing a holistic understanding of CBD’s efficacy and mechanisms in the context of sports recovery. The protocol for this integrative systematic review was registered in PROSPERO (ID: CRD42023479815) to ensure transparency and minimize potential bias.

Eligibility Criteria

To identify relevant studies in the use of cannabidiol (CBD) for sports recovery, this systematic review used a structured set of eligibility criteria following the PICOS (Population, Intervention, Comparator, Outcomes, Study design) framework (Page et al., 2021). Additionally, studies were excluded following this criteria: (1) if the article was not written in English; (2) if the full-text was not available, (3) if the type of document was doctoral thesis, books or book chapters, conference papers, patents or low-quality articles with a severe lack of information (number and characteristics of participants, design, methodology, CBD dose, etc.). The eligibility criteria were shown in Table 1.

Table 1.
Eligibility criteria

PICOS	Inclusion criteria	Exclusion criteria
Population	Studies involving humans (e.g. athletes and healthy individuals), as well as animal models (e.g. mice, rats).	Studies that do not involve humans or animals.
Intervention/ Exposure	Examining the use of CDB in any formulation (e.g. oral, topical) or dosage as a primary intervention.	Not examining the use of CBD as primary intervention.
Comparator	Studies with a placebo or control group were included, as well as those without a comparator.	None.
Outcomes	Studies reporting outcomes related to sports/exercise recovery, physical performance, and/or physiological effects of CBD (e.g. inflammation, pain, sleep, cognition).	Studies that report only the psychoactive effects of CBD.
Study design	Scientific evidence classified as a first and second level were incorporated (Medina et al., 2006), that Included experimental (randomized trials, non-randomized trials), observational (cohort, case-control), and systematic reviews/meta-analyses.	Studies were non-empirical or lacked sufficient methodological details.

Search Strategy and Article Management Process

The search strategy for this integrative systematic review was designed to capture a comprehensive body of literature related to the use of cannabidiol (CBD) in sports recovery. An initial exploratory search was conducted to identify relevant keywords, controlled vocabulary terms, and subject headings across different disciplines related to the topics of CBD, sports, exercise, recovery, fatigue, and performance. The search terms were selected or adapted based on the Medical Subject Headings (MeSH) descriptor data from the National Library of Medicine. Once this initial identification of relevant descriptors was made, the words chosen for the formal search were: “(cannabidiol OR CBD) AND (sports OR exercise OR physical activity) AND (recovery of function OR fatigue OR sports performance OR injury OR inflammation OR muscle fatigue).”

Then, the formal search was then performed on October 30th, 2023 by two independent reviewers in three electronic databases: PubMed (MEDLINE), Scopus (EMBASE) and Web of Science (Web of Science Core Collection, MEDLINE, Current Contents Connect, Derwent Innovations Index, KCI-Korean Journal Database, Russian Science Citation Index and Scielo Citation Index). Additionally, the reference lists of included studies were manually screened to identify any potentially relevant publications that may have been missed in the initial search. All references were extracted and imported into an open-source research tool (5.0.64, Zotero, CA, United States) to subsequently systematize the studies (Excel, Microsoft, CA, United States). All duplicates found among the databases were identified and eliminated.

Study selection

The selection of studies for inclusion was guided by the predetermined eligibility criteria outlined previously, considering empirical data, theoretical perspectives, or literature reviews related to the use of CBD in the context of sports, exercise, recovery, fatigue, or performance. Firstly, the title and abstract screening was conducted independently by two reviewers. Any disagreements that arose during this initial screening phase were resolved through discussion between the two reviewers.

The articles that passed the title and abstract screening then underwent a full-text assessment for final eligibility. During this stage, the full manuscripts were reviewed to ensure the studies met all the inclusion criteria. Only those studies that were deemed eligible based on the full-text review were selected for data extraction and synthesis. The PRISMA flow of the integrative review can be analyzed in Figure 1.

Figure 1.
Flowchart of article identification, selection, and exclusion

Study Quality Assessment

For assessing the preclinical animal studies, the ARRIVE guidelines have been used (Percie du Sert et al., 2020). The selected studies obtained moderate to high methodological quality. Most of them clearly report the study objectives, animal characteristics, experimental procedures, and statistical analyses. However, some studies do not include important aspects such as randomization, blinding, and sample size calculations, which are important to ensure internal validity and minimize bias. Additionally, most of them recommended replicating and extending their findings in the future, suggesting the need for more robust preclinical evidence.

The clinical studies involving human participants were assessed using the Cochrane Risk of Bias 2 (RoB 2) tool (Crocker et al., 2023). The risk of bias across the studies was generally low to moderate. Most studies demonstrated appropriate randomization, blinding, and handling of missing data. Instead, some studies had concerns that could introduce potential sources of bias like the selection of the reported results and the overall study design. It is necessary to conduct larger, well-designed, and adequately powered clinical trials to establish further the efficacy and safety of cannabidiol (CBD) in various medical conditions.

The studies under review and meta-analysis were assessed using the AMSTAR checklist (Shea et al., 2017). The methodological quality of these studies was found to be moderate to high. The authors of the reviews provided a comprehensive search strategy, clearly defined the inclusion criteria and conducted a thorough quality assessment of the included studies. When a disagreement was evident, it was solved with a third-party opinion. However, certain reviews did not provide details on the rationale for excluding studies, the evaluation of publication bias, or the exploration of potential sources of heterogeneity. These areas should be improved in future review-level evidence to enhance the reliability and robustness of the conclusions.

In summary, the analysis of the study methods across the preclinical, clinical, and review levels of evidence indicates that the overall quality is acceptable, with some opportunities for improvement. Improving methodological rigor, specifically in areas such as randomization, blinding, and sample size calculations, will help enhance the validity and reproducibility of the findings. In addition, more well-designed, large-scale clinical trials and comprehensive systematic reviews are needed to elucidate the therapeutic potential of cannabidiol (CBD) and its fundamental mechanisms of action.

Data extraction

The data extraction process involved compiling key information from the included studies into a standardized spreadsheet. Two independent reviewers extracted the following data elements:

a) Authors and year of publication: The full citation details, including the year the study was published.

b) Main aim: The primary objective or research question addressed by the study.

c) Methodology:

c.1) Subjects: The participant characteristics, such as species (human, animal), population (athletes, healthy individuals), age, sex, etc.

c.2) Study design: The type of study design (e.g. randomized controlled trial, observational, systematic review).

c.3) CBD supplement: Details on the CBD intervention, including the formulation (oral, topical, etc.), dosage, and administration protocol (dose, frequency, timing).

d) Main results (CBD effects): The key findings and conclusions related to the effects of CBD, such as impact on recovery, performance, inflammation, pain, sleep, etc.

e) Recommendations for future research: Any suggestions or directions for further study proposed by the authors.

The reviewers worked independently to extract this information, with any discrepancies resolved through discussion and consensus. This systematic data collection process ensured comprehensive and accurate extraction of the relevant study details.

RESULTS

Search, selection and inclusion of publications

1761 articles were identified from the Web of Science (n = 630), PubMed (n = 728) and Science Direct (n = 403) database search. In the screening phase, 1322 articles were deleted due to the year of publication, the title of the article or abstract. From the remaining 439 papers in the eligibility phase, they were exported to a reference manager (Zotero), and any duplicates (76 articles) were eliminated automatically. Finally, 363 articles arrived at the last phase, where 288 did not fulfill the inclusion criteria and 5 had methodological doubts, so 293 articles were removed. At the end of the screening procedure, 70 articles remained for the systematic review related to the study topic that were included in Table 2, indicating authors and year of publication, main aim, methodology (subjects, study design and CBD supplement, including periodization and dose characteristics), main results (CBD effects) and recommendations for future research.

Type of study, subjects and clinical evidence of CBD

Regarding the type of study, preclinical studies represent 38.57% (n=27), clinical studies represent 31.43% (n=22), and reviews and meta-analyses represent 30.00% (n=21). Various populations were evaluated during the studies, such as mice (26%), rats (37%), epileptics (16%), men (8%), women (9%), girls (2%), and rugby players (2%). Respect to clinical evidence, 22% of selected studies reporting its beneficial effect during the pathology treatment, 17% on anxiety, 17% on anti-inflammatory characteristics, 11% exploring its effects on sleep, and 6% on muscle recovery in athletes.

Effects of CBD, doses and administration methods

The effects of CBD are varied, among which 39% refer to studies with anti-inflammatory effects, 22% on disorders (fibrosis, asthma, chronic pain), another 22% are studies on muscular recovery and as a therapeutic agent and 17% on studies about the benefits as a neuroprotector. The doses used were 5-10mg (21%), 20-30mg (43%), 300-600mg (36%), other doses used in a smaller percentage were 60mg, 0.005-5mg, 50mg, 150mg, and 120mg. Additionally, CBD was administered mixed in a medium such as oil in 6%, orally in 33%, intravenously in 40%, aerosol, intracerebroventricular, subcutaneous, and intraperitoneal in 7%, and with a plug in a single dose (n=1, 0.01%).

Table 2.
Summary of first and second-level scientific evidence related to the biomedical properties of cannabidiol

#	Authors	Aim	Methodology	Main results (CBD effects)	Recommendations for future research
Preclinic research (animals) (n= 27)
1	Zieba et al. (2019)	Effect of CBD on anxiety-related behavior	n = 72 mice with acute administration of CBD at 5-20 mg/kg versus control	Better adaptation to the new anxiolytic environment	Clarify the relationship between CBD and pre-pulse inhibition.
2	Schleicher et al. (2019)	Effect of CBD on behavioral profile, motor performance, anxiety, and memory	Acute administration of CBD in mice at 20 mg/kg for six months versus control	Non-negative effects	Optimal treatment strategies.
3	Myers et al. (2019)	Effects of CBD on cognition	n = 335 mice Acute CBD intake at 3-10 mg/kg, chronic at 5-20 mg/kg	Anxiolytic	More suitable animal models.
4	Iannotti et al. (2019)	Effect of cannabinoids (CBD) on inflammation, functional autophagy, and improvement of muscle function	Mice, muscular dystrophies Chronic intake of CBD at 60 mg/kg, three times per week for two weeks	Improved structural and functional muscle enhancement and recovery	Replication and extension of findings.
5	Santiago et al. (2019)	Effects of CBD on neuroplasticity, inflammation, and cognitive function	Diabetic rats Chronic CBD at 10 mg/kg, once a day for 30 days.	Reduction of blood glucose levels, cognitive enhancer, reduction of neurodegeneration and inflammation, and attenuation of decreased levels of BDNF (neuroprotective)	Effects of low-high dose ratio of THC and CBD administration.
6	Casey et al. (2017)	Effects of cannabinoids on neuropathic pain	Mice, chronic constriction injury 0.01-0.015 mg/g	Potential in the treatment of neuropathic pain Anti-allodynic properties	Confirm results.
7	Hayakawa et al. (2007)	Effects of CBD as a neuroprotective agent.	Mouse, cerebral ischemia Dissolved at 1%	Neuroprotection through an anti-inflammatory mechanism of the CB1 receptor	Confirm chronic effects of CBD administration on cerebral ischemia.
8	Mori et al. (2017)	Effects of CBD on functional recovery after cerebral ischemic injury	Mice, bilateral common carotid artery occlusion Short-term 10 mg/kg CBD before and after the event	Prevention of anxiety-like behavior, memory impairments, and despair-like behavior	Clarify the relationship between CBD and pre-pulse inhibition.
9	Murillo-Rodríguez et al. (2018)	Effects of CBD on neurochemicals related to wakefulness	Rats, microdialysis surgeries Intravenous dose of 5-30 mg/kg	Increases acetylcholine levels in a brain region related to wakefulness control.	Clarification of how CBD induces improvement in neurobiological processes involving acetylcholine.
10	García-Baos et al. (2021)	Effects of CBD demonstrating that Phytocannabinoid could attenuate alcohol-induced cognitive deficits	n = 6 rats. CBD (20 mg/kg ip). 10 ml alcohol or water	Counteract neuroinflammatory-induced cognitive impairments with PLAE treatment with CBD.	Further studies evaluating dose-dependent positive or adverse effects of CBD.
11	Mukhopadhyay et al., (2011)	Effects of cannabidiol (CBD) on myocardial dysfunction, inflammation, oxidative/nutrient stress, cell death, and interrelated signaling pathways	Mice. Dose of 50 mg/kg dissolved in 100 ml citrate buffer pH 4.5 for 5 consecutive days.	Did not alter glucose levels. Improved myocardial dysfunction.	CBD as a potential therapeutic in the treatment of diabetic cardiovascular conditions and oxidative stress.
12	Gregorio et al. (2019)	Determining whether acute CBD administration modulates DRN 5-HT neuronal activity and effect of repeated treatment with low doses of CBD on mechanical allodynia	Rats. Acute increasing intravenous doses of CBD (0.1-1.0 mg/kg). Repeated treatment with CBD (5 mg/kg/day, subcutaneously)	Repeated CBD treatment could prevent mechanical allodynia and anxiety-like behavior.	Repeating with low doses of CBD induces analgesia and reduces anxiety.
13	Bis-Humbert et al. (2021)	Comparing the antidepressant-like response induced by cannabidiol	Rats. 3, 10, and 30 mg/kg	Decreased body weight. Improved despair-like behavior. Did not modulate anxiety-like behavior.	Support the idea that cannabidiol exerts antidepressant and anxiolytic effects.
14	Borys et al. (1979)	Effects in mice of both acute and subacute CBD treatment on sleep time	Rats. 120 mg/kg	Significant increases in sleep.	Inhibitory action of CBD is still unknown.
15	Peres et al. (2016)	CBD treatment would attenuate motor and cognitive impairments	Rats. 0.5 or 5 mg/kg	CBD improves motor and cognitive impairments.	Include CBD in the pharmacotherapy of Parkinson’s disease.
16	Vuolo et al. (2015)	Effects of CBD on inflammatory parameters (evaluated by cytokine levels) in an asthma model.	Rats. Dose of 5 mg/kg.	Significantly reduced cytokine levels, exhibiting anti-inflammatory effects.	Beneficial effect of CBD in an animal model of asthma.
17	Wheal et al. (2014)	CBD effect decreases insulitis, inflammation, neuropathic pain, and myocardial dysfunction in preclinical models	Rats. Dose of 10 mg.	Relaxing	Improves the ability of arteries to relax through increased production of vasodilatory products.
18	Hammell et al. (2016)	Cannabidiol (CBD) attenuates inflammation and pain without side effects	Rats.	Reduced joint inflammation.	Effective doses for reduce inflammation.
19	Belardo et al. (2019)	Effects of CBD on neurological dysfunctions associated with TBI	Dose of 0.6 to 6.2 mg/day.	Restored behavioral alterations and partially normalized cortical biochemical changes.	CBD as a pharmacological tool to improve neurological dysfunctions caused by trauma.
20	Ceprián et al. (2017)	Protective effect of CBD in a neonatal rat model of AIS.	Dissolved in hemp seed oil and tocopherol. CBD (30 μl, 10% oil).	Improved neurobehavioral function in terms of strength, hemiparesis, coordination, and sensorimotor performance.	CBD administration following middle cerebral artery occlusion (MCAO).
21	Costa et al., (2004a)	Anti-inflammatory and anti-hyperalgesic effects of cannabidiol	Rats. Dose of 5 mg/kg intraperitoneally.	Anti-hyperalgesic effect.	Beneficial effect on two inflammation symptoms.
22	(Costa et al. (2004b)	Anti-hyperalgesic effect of CBD	Rats. Oral dose (5-40 mg/kg).	Anti-hyperalgesic effect.	The potential involvement of transient receptor potential vanilloid type 1 receptor. Could be a molecular target of anti-hyperalgesic action.
23	Costa et al. (2007)	Therapeutic potential in neuropathic pain.	Rats. Oral dose of 10 mg kg-1 (5 ml kg-1).	Anti-inflammatory and immunomodulatory effects.	Therapeutic use for pain.
24	Ignatowska-Jankowska et al. (2011)	Effects of repeated CBD administration on body weight gain in rats	Rats. at doses of 2.5 and 5 mg/kg/day	Ability to modulate weight gain.	Further investigation into the regulation of body weight.
25	Murillo-Rodríguez et al. (2006)	Effects of CBD on sleep	Rats. Doses of 10mg/5mg intracerebroventricularly	Modulates wakefulness.	Addressing vanilloid receptors.
26	Schiavon et al. (2014)	Cannabidiol, one of the main non-psychoactive components	Mice. Doses of 3, 10, and 30 mg/kg	Protective effect of CBD on neuronal death.	The mechanisms underlying the neuroprotective effects of CBD.
27	Wang et al. (2017)	Effects of CBD on alcohol-induced chronic and compulsive feeding-induced liver injury.	Mice. Doses: ethanol (5 g/kg body weight) and 5 or 10 mg/kg/day of CBD.	Antioxidant, cytoprotective, and anti-inflammatory properties. Attenuates chronic liver injury and ethanol-induced steatosis.	Therapeutic potential in liver diseases associated with inflammation, oxidative stress, metabolic dysregulation, and steatosis.
Clinical studies in humans (n=19)
28	Zuardi et al. (1993a)	Explore the effect of CBD and aspirin in stressful situations.	n = 40 (♂ = 18, ♀ = 22), CBD single healthy doce at 300 mg dissolved in corn oil (100 mg / ml)	Anxiolytic	Realize confirmatory analysis of results
29	Zuardi et al. (1993b)	Explore the effects of CBD on plasma prolactin, growth hormone, and cortisol.	n = 11, healthy Single dose of CBD at 300 mg and 400 mg	Sedative and anti-inflammatory	Realize confirmatory analysis of results
30	Martin et al. (2019)	Long-term effects of CBD on cognitive function.	n = 27, epilepsy Annual CBD intake of 36,5 mg / kg / día	No effects on cognitive function	Realize new studies with Randomized, placebo-controlled, and larger samples.
31	Allendorfer et al. (2019)	Effects of CBD oral solution on attention.	n = 22 epilepsy 25 mg / kg / d for at least 2 weeks	No effect on mood	Controlled trials and examination of long-term effects, follow-ups after treatment.
32	Santos de Alencar et al. (2021)	Reduce tremors in patients with ET.	n=19 ET patients. Oral dose of CBD (300 mg).	A single dose had no effect on upper limb tremors	Chronic treatment with CBD.
33	Kasper et al. (2020)	Prevalence of CBD use in professional rugby league and union players.	n=517 rugby players. Survey.	CBD use showed improvement in recovery/pain (80%) and sleep (78%), and 68% of players reported a perceived benefit	Need to explore claims regarding pain and sleep.
34	Cochrane-Snyman et al. (2021)	Effect of CBD oil on perceived muscle pain, inflammation, and strength performance.	n=13 men Dose: 150 mg.	They did not support that supplementation with CBD oil would have an effect on muscle damage and inflammation after an ECC protocol.	Investigate broader ranges of CBD dosage and scheduling in trained and untrained men and women.
35	Neubauer et al. (2018)	Evaluate the effectiveness of complementary therapy with CBD.	Patients with epilepsy. Dose of less than 8 mg/kg/day.	Less intense seizures, shorter seizure duration, shorter recovery time, and other positive side effects of CB treatment.	Potential benefits as adjunctive therapy.
36	Lopez et al. (2020)	Effects of a CBD oil extract on stress resilience, perceived recovery, mood, affect, and body composition.	65 men and women. Dose of 60 mg.	Improved HDL cholesterol, supported psychometric measures of sleep, stress response, and perceived vitality.	Supplementary use.
37	Hatchett et al. (2020)	Determine the influence of cannabidiol oil in attenuating delayed onset muscle soreness.	N=23. Dose of 16.67 mg.	Muscle recovery	Investigate the role of CBD dosage level, nutrition, sleep, exercise type, and other factors on CBD’s ability to attenuate exercise-induced muscle damage effects and aid in the recovery process.
38	Sahinovic et al. (2022)	Effects of acute CBD treatment on physiological and psychological responses to aerobic exercise	n=9, trained males (57.4±4 ml/kg/min) CBD (300 mg) vs Placebo 1.5h before exercise	CBD appeared to increase VO2, ratings of pleasure and blood lactate compared to placebo.	Larger studies are required to confirm and better understand these preliminary findings.
39	Alhamoruni et al., (2012)	Determine if cannabinoids modulate increased permeability associated with inflammation in vitro.	Dose of 10 ng · mL -1.	Recovery of increased permeability	Locally produced endocannabinoids, acting through CB1 receptors, play a role in mediating changes in permeability with inflammation.
40	Arndt & de Wit (2017)	Effects of CBD on responses to negative emotional stimuli as a model for its potential anxiety-reducing effects.	n=38. Oral CBD 300, 600, and 900 mg.	CBD did not produce detectable subjective effects or alterations in mood or anxiety.	Further research on the behavioral and neural mechanisms of CBD and
41	Bergamaschi et al., (2011)	Effects of a simulated public speaking test.	N=24 CBD dose of 600 mg	Reduced anxiety, cognitive impairment, and discomfort in speech performance, and decreased anticipatory speech alertness.	More research to determine the precise mechanisms of action of CBD in different anxiety disorders.
42	Birnbaum et al. (2019)	Evaluate the pharmacokinetics of an oral cannabidiol capsule with and without food.	n=8. Dose of 99% pure CBD capsules on an empty stomach as well as under fed conditions.	More precise pharmacokinetic parameters	Use of CBD capsules
43	Jadoon et al. (2017)	Investigate if CBD reduces blood pressure in humans.	n=9. Dose of 600 mg.	Reduces resting blood pressure and attenuates blood pressure increase during stress	Research to establish if CBD has a role in the treatment of cardiovascular disorders.
44	Kraft et al. (2008)	Effects of oral cannabis extract in two different human models of acute inflammatory pain and hyperalgesia.	n=18 women. Oral capsule administration.	Hyperalgesic	Future clinical studies in patients with chronic pain
45	Linares et al. (2018)	Effect of a clinically anxiolytic dose of CBD on the sleep-wake cycle.	n=27. Dose of 300 mg.	Does not interfere with the sleep cycle	Address the effects of CBD on the sleep-wake cycle in patient populations
46	Masataka (2019)	Evaluate the efficacy of CBD treatment for adolescents with social anxiety disorder.	n=17. Dose of 300 mg.	Reduced anxiety	Useful option for treating social anxiety.
47	Shannon & Opila-Lehman (2016)	Evidence that CBD is effective as a safe alternative treatment to traditional psychiatric medications for reducing anxiety and insomnia.	n=1, 10-year-old girl. CBD supplements (25 mg) at bedtime, and 6 mg to 12 mg of sublingual CBD spray administered during the day	Reduces anxiety and improves sleep	Study long-term effects.
48	Isenmann et al. (2021)	Effect of CBD after resistance training on performance and muscle damage	n=21 CBD after exercise (60mg on 250 mL water) vs Placebo	Small significant effects on muscle damage and recovery after 72 h in CBD group vs Placebo	More data are required for clearer statements concerning potential pro-regenerative effects of CBD
49	Crossland et al. (2022)	Determine that CBD is effective to reduce inflammation and enhances performance for strenuous eccentric exercise	27 female (18-26 years-old) Isolate CBD (5 mg/kg; 3 times -2h, 0h and +10h) vs Placebo	No effect for inflammation, muscle damage and subjective fatigue	Study of varying CBD supplements to determine if other phytochemicals in cannabis plant prove effective for recovery
Reviews and meta-analysis (n=21)
50	McCartney et al., (2020)	Present preliminary preclinical laboratory animal data in humans, non-athletes.	Narrative review	Anti-inflammatory Neuroprotector Analgesic Anxyolitic	Rigorous and controlled studies in humans
51	Burggren et al., (2019)	Review the effects of CBD on brain structure, function, and cognition.	Literature review	Insufficient evidence	Short and long-term consequences Effect in older adults Efficacy and safety of existing products
52	Burstein (2015)	Review the effects of CBD on inflammation.	Literature review	Anti-inflammatory Decrease of secondary inflammatory effects	Human trials with clinical application Advantages of CBD over other cannabinoids Synthetic analogs with greater potency than CBD
53	Hill et al. (2012)	Effects of phyto-cannabinoids (CBD) in preclinical models of central nervous system disease.	Literature review	Neuroprotective anticonvulsant (modulates immune cell activity and limits oxidative stress)	Long-term, double-blind, placebo-controlled trials are needed. Participants with different affective disorders.
54	Booz (2011)	Effects of CBD on inflammation and oxidative stress.	Narrative review	Anti-inflammatory Antioxidant	More details are needed on how CBD targets inflammatory signaling. Test studies on the therapeutic utility of CBD.
55	Lorenzetti et al., (2016)	Recent findings from human structural neuroimaging research.	Systematic review	CBD protects against these harmful effects in the hippocampus, prefrontal cortex, amygdala, and cerebellum.	Urgent development of consensus-based guidelines to quantify cannabis consumption and exposure in human studies.
56	Rojas-Valverde (2021)	Explore the potential role of CBD in sports recovery.	Narrative review	CBD has anti-inflammatory, antioxidant, anxiolytic properties, and improves sleep quality.	Specific investigations are required to determine if cannabis can provide indirect benefits to athletes.
57	Kramer et al. (2020)	Effects of chronic cannabis consumption on physiological parameters of sports performance.	Systematic review	It did not have a significant effect on athletic performance. Resting heart rate was the only physiological measure that differed.	Specific investigations are required to determine if cannabis can provide indirect benefits to athletes.
58	Singh & Neary (2020)	Neuroprotective effects of cannabinoids, specifically the phytocannabinoid CBD, after a traumatic brain injury (TBI).	Systematic review	Enhancing neuroprotection by reducing inflammation.	Influence the blood-brain barrier, brain-derived neurotrophic factors, cognitive ability, brain vasculature, cardiovascular physiology, and neurogenesis.
59	Reillo (2019)	Examine sport-related traumatic brain injury and the preventive and therapeutic use of cannabidiol among athletes.	Systematic review	Efficacy of preventive and therapeutic administration of cannabidiol (CBD) in head injuries.	Recommended as a preventive and therapeutic intervention in the treatment of traumatic brain injury.
60	Fine & Rosenfeld (2013)	Link the endocannabinoid system and phytocannabinoids to their potentially therapeutic role in chronic pain management.	Systematic review	Analgesic for chronic pain.	Administered orally.
61	Sholler et al. (2020)	Synthesize the efficacy of CBD as a therapeutic agent.	Systematic review	Efficacy of CBD as a therapeutic for various medical conditions, including epilepsy, anxiety, pain/inflammation, schizophrenia, and substance use disorders.	Rigorous and controlled evidence of the therapeutic efficacy of CBD is lacking.
62	Lowin et al. (2019)	General effects of cannabinoids on inflammation.	Systematic review	Anti-inflammatory effects.	Targeting the right receptors in the right place.
63	Stanley et al. (2013)	Establish whether the cardiovascular system is a potential therapeutic target for CBD.	Systematic review	CBD reduces the cardiovascular response to stress models.	More evidence of the positive role of CBD in the heart.
64	Bruni et al. (2018)	Synergistic effect in pain treatment.	Systematic review	Therapeutic, anti-inflammatory.	Further assessment of nanotechnology systems.
65	Zurier & Burstein (2016)	Ability to facilitate inflammation resolution.	Systematic review	Anti-inflammatory Reduction of fibrosis	Cannabinoids becoming safe and effective anti-inflammatory medications.
66	Vuolo et al. (2019)	CBD in respiratory pathways remodeling.	Systematic review	Anti-inflammatory Reduction of asthma	More details on airway remodeling.
67	Crippa et al. (2011)	Investigate generalized social anxiety disorder (GSAD) using functional neuroimaging.	Preliminary report	Reduction of anxiety	Effects on activity in the limbic and paralimbic areas of the brain.
68	Huestis et al. (2011)	Support the status of cannabis regarding the Prohibited List.	Systematic review	Positive effect on performance	Further research on the development of tolerance after long-term frequent exposure.
69	Lattanzi et al. (2018)	Efficacy and safety of CBD as an adjunctive treatment in patients with epilepsy.	Systematic review and metanalysis	Reduction of seizures frequency	Does not produce euphoric or intrusive side effects.
70	Ware et al. (2018)	Identify and highlight challenges in interpreting information regarding elite athletic performance and identify important areas of research that need to be addressed.	Literature review	Promising effect for the treatment of chronic pain.	There is no evidence that cannabis consumption is a performance-enhancing drug.

DISCUSSION

Preclinic research (animals)

Despite the relatively popular use of cannabinoids in humans, most of the actual evidence on the effects of CBD on physiological and psychological effects focuses on animals, especially pigs, mice, and rats. The lack of clinical trials could be due to national and international restrictions on access to cannabinoids, including CBD, and strict control of their use for research purposes. Other limitations are rigorous procedures for trial approval by government drug agencies. Therefore, preclinical studies have been conducted to determine the safe initial dose and assess the potential toxicity of CBD before testing it in humans.

Some preliminary studies have found some benefits of CBD consumption in both physiological and cognitive functions. Recent evidence suggests a reduction in anxiety and better adaptation to new environments when CBD is prescribed in mice (Myers et al., 2019; Zieba et al., 2019). In contrast, other studies suggest no benefits on anxiety in response to CBD administration but have not found negative effects (Schleicher et al., 2019). Novel studies have suggested a neuroprotective consequence of CBD administration, leading to a decrease in attenuation in BNDF levels related to the reduction of neuroinflammation (Santiago et al., 2019), and some neuroprotection after a stroke event (Hayakawa et al., 2007), stimulating neurogenesis and promoting dendritic restructuring in the hippocampus (Mori et al., 2017). CBD also showed potential in the treatment of central and peripheral neuropathic pain (Casey et al., 2017) and some increases in acetylcholine in the brain after its administration were reported (Murillo-Rodríguez et al., 2018). In addition, it was found to exert antidepressant and anxiolytic effects at the cognitive level, with only positive and beneficial evidence for functional recovery and anti-inflammatory symptoms (Murillo-Rodríguez et al., 2018).

Regarding muscle function and anti-inflammatory effects of CBD administration in animals, a revealing study found that CBD intake could lead to structural and functional improvement of muscles, suggesting muscular recovery (Iannotti et al., 2019). This study explained that CBD could promote the differentiation of myoblast cells into myotubes by increasing Ca2+, thereby preventing locomotor activity loss related to the reduction of proinflammatory markers in tissue and plasma, and restoring autophagy. The results of this main study on the anti-inflammatory effects of CBD are supported by additional evidence, recognizing its use as a potential new treatment in the inflammatory response and reduction of chronic pain (Santiago et al., 2019). Hammell et al. (2016) and Vuolo et al. (2015) also found a positive relation of CBD with anti-inflammatory parameters (reduction of cytokine levels). Other studies have found the benefits of CBD consumption regarding sleep disorders in animals, showing that it can prolong sleep time and prevent excessive drowsiness (Borys et al., 1979; Murillo-Rodríguez et al., 2006; Santiago et al., 2019).

Notwithstanding the notable physiological differences between animals and humans, these results indicate promising potential for CBD to improve muscular recovery. The data suggest that CBD may modulate inflammation and thereby accelerate healing stages, such as inflammation, proliferation, and regeneration, following tissue damage. While extrapolation to healthy humans or athletes is premature, the results merit further research on CBD’s utility in recovery from muscular injury in both animals and humans.

Exercise-induced fatigue and damage in humans trigger physiological and psychological cascades. Extensive research, including studies, guidelines, reviews, and meta-analyses, has examined exercise fatigue to elucidate the central and peripheral mechanisms disrupting bodily function.(Martínez-Guardado et al., 2020) Common delayed-onset symptoms like sleepiness, swelling, pain, and weakness often persist hours or days post-exertion (Kreher & Schwartz, 2012). This review synthesizes human evidence on CBD’s potential to improve recovery. Elucidating CBD’s effects on inflammation, sleep, pain, and other cognitive and psychological outcomes in healthy and pathological populations could inform future applied research on CBD in sports science and medicine.

Noninflammatory and antioxidant effects in humans

Eccentric exercise can induce sarcolemma damage by altering muscle cell membrane permeability and the basement membrane, enabling Ca++ influx that disrupts muscle fiber electrochemical gradients. If sarcolemma damage is modest, ATPase pumps can restore Ca++ homeostasis and reverse the damage. However, Ca++ overload initiates degradation of structural and contractile proteins, eliciting an inflammatory cascade involving macrophage and phagocyte activation within 2-6 hours post-injury, persisting for days (Armstrong et al., 1991; Burstein, 2015).

A single 300mg CBD dose alters human glucocorticoid levels, including the key inflammatory regulator cortisol (Zuardi et al., 1993b), which is considered as one of the main homeostatic regulators of the inflammatory response to injury (Yeager et al., 2010). A recent narrative review proposed CBD’s anti-inflammatory effects in humans could benefit athletic performance (McCartney et al., 2020), potentially by interacting with inflammation-modulating receptors (e.g., CB1, CB2, A2A) and attenuating pro-inflammatory cytokines, including IL-1, TNFα, thus suppressing hyperactive immune responses and associated tissue damage (Booz, 2011; Burstein, 2015; Hill et al., 2012). There is also evidence suggesting the potential of CBD to promote the release of arachidonic acid, leading to greater healing capacity as a result of central regulation of growth signals mediated by pro-resolving substances such as lipoxin A4 and 15d-PGJ2 (Burstein, 2015).

CBD may confer neuroprotection by reducing inflammation, protecting the brain and heart, and attenuating cardiovascular responses (Burstein, 2015). As CBD resolves chronic inflammation via phytocannabinoids, it could have therapeutic efficacy in conditions like epilepsy and Parkinson’s disease (Burstein, 2015). It is also known that many human diseases, resulting from tissue and organ damage, are underpinned by the interaction between inflammation and oxidative stress (Gamelin et al., 2020). In this sense, in sports, the hypothesis is raised that this CBD related to inhibitions of oxidative stress and neuroinflammation could have some therapeutic potential in sports research.

Pain and discomfort in humans

In sports, changes in muscle structure in response to damage can cause pain. Maximum pain is experienced 2-3 days after exercise because of prostaglandins produced by monocytes, which sensitize afferent nerve endings in the muscles and cause a sensation of discomfort felt as fatigue and tension (nociceptive pain). Swelling causes pain, and after intense exercise, maximum swelling typically occurs five days after exertion due to increased muscle pressure as a result of inflammation (inflammatory pain) (Clarkson et al., 1992). Both pain and swelling can cause a reduction in muscle shortening capacity, limitations in mobility and range of motion, decreased sleep quality, reduced muscle strength, and other reductions in neuromechanical function; that is why research on effective and efficient recovery methods is crucial in sports (Hainline et al., 2017; Rudroff & Sosnoff, 2018).

The delayed onset of muscle pain due to damage from physical activity, as well as the management of chronic pain, are part of the therapeutic benefits of using CBD in sports performance, also improving sleep and therefore mood (Hainline et al., 2017; Rudroff & Sosnoff, 2018). They can also include the potential of reducing resting blood pressure as a potential that improves athletic performance and regulation of body weight by CB2 receptors (Hainline et al., 2017; Rudroff & Sosnoff, 2018).

Currently, there is very limited evidence about the ingestion of CBD and its sedative effect. In this sense, 300-400 mg of CBD seems to have sedative effects in humans due to its apparently acting direct on the central nervous system (Zuardi et al., 1993b), supported by the idea that CBD has a beneficial action on edema and hyperalgesia (Burstein, 2015; Hill et al., 2017). In this sense, in many countries, drugs such as Sativex, THC, and CBD are approved for the treatment of both central and peripheral neuropathic pain, which is associated with microglial activation and subsequent proinflammatory cytokine cascades such as IL-6, IL-1β, and TNFα; this supports the idea of using CBD as an anti-nociceptive agent (Booz, 2011). This effect, along with other neuroprotective qualities, was also found in a recent systematic review of the outcome of CBD ingestion concerning its potential use as a substance to enhance sports performance (McCartney et al., 2020).

Sleep quality

Sleep disorders are relatively common among athletes when recovering from fatigue injuries. Athletes are recommended to sleep for 7 to 10 hours per night, and the usual duration of sleep is less than 8 hours per night, increasing the risk of injury. The duration of sleep, but not sleep quality, appears to have an impact on performance (Fox et al., 2020).

Sleep and pain have a reciprocal relationship, with greater pain resulting in greater sleep disturbance, as well as poor sleep quality and higher levels of pain. Some strategies, such as mindfulness, self-hypnosis, meditation, and stress or anxiety reduction techniques, show significant potential for sleep improvement (Hainline et al., 2017). Additionally, other psychological factors may potentially influence sleep, such as overtraining, which often occurs when intensified training and competition are accompanied by insufficient recovery (Fox et al., 2020). Some natural alternatives have been proposed, such as infusions, hot showers, tea consumption, and the use of oil as sleep and anxiety improvement strategies (Verma et al., 2022). Based on these effective benefits, some team sports athletes have widely used CBD for sleep, pain relief, and recovery, and its consumption increases with age (Kasper et al., 2020). Endocannabinoid system stimulation may modulate sleep disorders in aging, being very promising evidence for sports while some elements of this system modulate the sleep-wake cycle (Murillo-Rodríguez et al., 2020).

Cognitive and psychological effects

Regarding the effect on cognition and mood, there is evidence suggesting the absence of benefits after prolonged use of CBD in humans (Allendorfer et al., 2019; Martin et al., 2019). On the other hand, a single administration of 300 mg of CBD has been reported to have an anxiolytic effect in healthy humans (Zuardi et al., 1993a). Specifically in sports, athletes, due to their competitive nature, tend to exhibit exaggerated behaviors. This can lead to states of high anxiety and even in some situations can trigger states of depression. In this sense, CBD could have anxiolytic and antidepressant actions through the activation of 5-HT1A receptors, but more evidence is needed to consider these conclusions strong enough (Booz, 2011).

Preliminary studies show that CBD protects against neuroanatomical alterations. This is significant as emotional stimuli can be determinants in sports performance, such as anxiety, and they are reduced with the useful use of cannabidiol on the limbic and paralimbic areas of the brain (Booz, 2011). Finally, the potential use of CBD in sports performance as an anxiolytic substance has been explored, with authors linking the possible effect on exercise with previous clinical and preclinical studies in animals, healthy populations, and patients with underlying pathologies (McCartney et al., 2020).

Study limitations

Due to the lack of research in sports medicine and science, the main limitation is the struggle to extrapolate the benefits found in animals, healthy humans, and patients with pathologies to potential applications in sports science. There is a need for new evidence in humans considering the lack of available information, knowing an exact dosage, and relatively common methodological flaws in accessible research. The relatively low rate of publications analyzing the effects of CBD on variables related to recovery led to a large amount of duplicated information among databases. The way some studies approach the descriptors cannabinoids, CBD, cannabis, and THC generates confusion, due to some flaws in the presentation of methodology, which make interpretation of results difficult. As a result of the different approaches of studies and methodological differences, it was difficult to systematize information. Although CBD has been shown to have a series of properties that may suggest its potential use in athletes, there are current conditions of sale and commercialization that require caution in its consumption. Poor manufacturing, THC present in CBD products and lack of product labeling and analytical reports could cause serious health problems and violations of doping regulations. In addition, the large doses of CBD used in the reviewed studies are not readily available to athletes without prescription.

CONCLUSIONS

CBD appears to have anti-inflammatory, neuroprotective, analgesic, anxiolytic, and potentially performance-enhancing properties in athletes, but further scientific evidence is necessary to confirm these effects. Confirmatory analyses using randomized placebo-controlled trials to test the acute and chronic effects of different dosing regimens are needed. These studies should consider fundamental aspects of sports, such as the variety of biological and situational conditions that contribute to fatigue, the characteristics of each discipline during training and competition, as well as individual athlete peculiarities, tolerance and response to CBD intake, and the combined effect of CBD administration with other physical and nutritional aids.

PRACTICAL APPLICATIONS AND FUTURE RESEARCH

Given the relatively common use of cannabis and CBD among athletes, there is a clear need to improve scientific understanding of the effects of CBD use on athlete recovery and performance. More scientific advances are needed, primarily the execution of experimental trials, which enable a deeper understanding of both positive and negative critical results for the ultimate benefit of athlete recovery and performance.

New randomized placebo-controlled studies should consider different etiologies of fatigue and damage, individualities and disciplines, needs and special characteristics. Other potential research areas include: (1) optimal dosing based on physical and physiological load, (2) the efficacy concerning the timing of CBD administration (before, during, or after training/competition), (3) the chronic versus the acute effects of CBD, (4) the cumulative responses with other recovery strategies, or (5) the differences in tolerance and efficacy by sex, professional level, fitness level, and other individual conditions. More information is needed on understanding CBD’s inflammatory signaling in the recovery process. Additionally, the effectiveness of CBD compared to conventional medication should be evaluated. The resulting evidence could provide new clinical guidance for prescribing CBD during the athlete’s recovery process and other potential applications. The possible therapeutic benefits of CBD administration have been minimized for years, but the actual scenario could facilitate increased knowledge about this natural compound and its effects. Moreover, a clearer and global policy for the use of cannabis in sports should be considered.

REFERENCES

Alhamoruni, A., Wright, K. L., Larvin, M., & O’Sullivan, S. E. (2012). Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability. British Journal of Pharmacology, 165(8), 2598-2610. https://doi.org/10.1111/j.1476-5381.2011.01589.x

Allendorfer, J. B., Nenert, R., Bebin, E. M., Gaston, T. E., Grayson, L. E., Hernando, K. A., Houston, J. T., Hansen, B., & Szaflarski, J. P. (2019). fMRI study of cannabidiol-induced changes in attention control in treatment-resistant epilepsy. Epilepsy & Behavior, 96, 114-121. https://doi.org/10.1016/j.yebeh.2019.04.008

Ament, W., & Verkerke, G. J. (2009). Exercise and fatigue. Sports Medicine (Auckland, N. Z.), 39(5), 389-422. https://doi.org/10.2165/00007256-200939050-00005

Armstrong, R., Warren, G., & Warren, J. (1991). Mechanisms of Exercise-Induced Muscle-Fiber Injury. Sports Medicine, 12(3), 184-207. https://doi.org/10.2165/00007256-199112030-00004

Arndt, D. L., & de Wit, H. (2017). Cannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults. Cannabis and Cannabinoid Research, 2(1), 105-113.
https://doi.org/10.1089/can.2017.0014

Belardo, C., Iannotta, M., Boccella, S., Rubino, R. C., Ricciardi, F., Infantino, R., Pieretti, G., Stella, L., Paino, S., Marabese, I., Maisto, R., Luongo, L., Maione, S., & Guida, F. (2019). Oral Cannabidiol Prevents Allodynia and Neurological Dysfunctions in a Mouse Model of Mild Traumatic Brain Injury. Frontiers in Pharmacology, 10, 352. https://doi.org/10.3389/fphar.2019.00352

Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., Martín-Santos, R., Hallak, J. E. C., Zuardi, A. W., & Crippa, J. A. S. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 36(6), 1219-1226. https://doi.org/10.1038/npp.2011.6

Birnbaum, A. K., Karanam, A., Marino, S. E., Barkley, C. M., Remmel, R. P., Roslawski, M., Gramling-Aden, M., & Leppik, I. E. (2019). Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia, 60(8), 1586-1592. https://doi.org/10.1111/epi.16093

Bis-Humbert, C., García-Cabrerizo, R., & García-Fuster, M. J. (2021). Antidepressant-like effects of cannabidiol in a rat model of early-life stress with or without adolescent cocaine exposure. Pharmacological Reports. https://doi.org/10.1007/s43440-021-00285-5

Booz, G. W. (2011). Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radical Biology and Medicine, 51(5), 1054-1061. https://doi.org/10.1016/j.freeradbiomed.2011.01.007

Borys, H. K., Ingall, G. B., & Karler, R. (1979). Development of tolerance to the prolongation of hexobarbitone sleeping time caused by cannabidiol. British Journal of Pharmacology, 67(1), 93-101. https://doi.org/10.1111/j.1476-5381.1979.tb16111.x

Bruni, N., Della Pepa, C., Oliaro-Bosso, S., Pessione, E., Gastaldi, D., & Dosio, F. (2018). Cannabinoid Delivery Systems for Pain and Inflammation Treatment. Molecules (Basel, Switzerland), 23(10), 2478. https://doi.org/10.3390/molecules23102478

Burggren, A. C., Shirazi, A., Ginder, N., & London, E. D. (2019). Cannabis effects on brain structure, function, and cognition: Considerations for medical uses of cannabis and its derivatives. The American Journal of Drug and Alcohol Abuse, 45(6), 563-579. https://doi.org/10.1080/00952990.2019.1634086

Burstein, S. (2015). Cannabidiol (CBD) and its analogs: A review of their effects on inflammation. Bioorganic & Medicinal Chemistry, 23(7), 1377-1385. https://doi.org/10.1016/j.bmc.2015.01.059

Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012). Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philosophical Transactions of the Royal Society B: Biological Sciences, 367(1607), 3364-3378. https://doi.org/10.1098/rstb.2011.0389

Carek, P. J., Laibstain, S. E., & Carek, S. M. (2011). Exercise for the treatment of depression and anxiety. International Journal of Psychiatry in Medicine, 41(1), 15-28. https://doi.org/10.2190/PM.41.1.c

Casey, S. L., Atwal, N., & Vaughan, C. W. (2017). Cannabis constituent synergy in a mouse neuropathic pain model. Pain, 158(12), 2452-2460. https://doi.org/10.1097/j.pain.0000000000001051

Ceprián, M., Jiménez-Sánchez, L., Vargas, C., Barata, L., Hind, W., & Martínez-Orgado, J. (2017). Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke. Neuropharmacology, 116, 151-159. https://doi.org/10.1016/j.neuropharm.2016.12.017

Clarkson, P., Nosaka, K., & Braun, B. (1992). Muscle Function After Exercise-Induced Muscle Damage and Rapid Adaptation. Medicine and Science in Sports and Exercise, 24(5), 512-520. https://doi.org/10.1249/00005768-199205000-00004

Cochrane-Snyman, K. C., Cruz, C., Morales, J., & Coles, M. (2021). The Effects of Cannabidiol Oil on Noninvasive Measures of Muscle Damage in Men. Medicine and Science in Sports and Exercise, 53(7), 1460-1472. https://doi.org/10.1249/MSS.0000000000002606

Costa, B., Colleoni, M., & Conti, S. (2004a). Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of Cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn-Schmiedeberg’s Archives of Pharmacology, 369(3), 294-299. https://doi.org/10.1007/s00210-004-0871-3

Costa, B., Giagnoni, G., Franke, C., Trovato, A., & Colleoni, M. (2004b). Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. British Journal of Pharmacology, 143(2), 247-250. https://doi.org/10.1038/sj.bjp.0705920

Costa, B., Trovato, A., Comelli, F., Giagnoni, G., & Colleoni, M. (2007). The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. European Journal of Pharmacology, 556(1-3), 75-83. https://doi.org/10.1016/j.ejphar.2006.11.006

Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L. S., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., Santos Filho, A., Freitas-Ferrari, M. C., McGuire, P. K., Zuardi, A. W., Busatto, G. F., & Hallak, J. E. C. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. Journal of Psychopharmacology (Oxford, England), 25(1), 121-130. https://doi.org/10.1177/0269881110379283

Crocker, T. F., Lam, N., Jordão, M., Brundle, C., Prescott, M., Forster, A., Ensor, J., Gladman, J., & Clegg, A. (2023). Risk-of-bias assessment using Cochrane’s revised tool for randomized trials (RoB 2) was useful but challenging and resource-intensive: Observations from a systematic review. Journal of Clinical Epidemiology, 161, 39-45. https://doi.org/10.1016/j.jclinepi.2023.06.015

Crossland, B. W., Rigby, B. R., Duplanty, A. A., King, G. A., Juma, S., Levine, N. A., Clark, C. E., Ramirez, K. P., & Varone, N. L. (2022). Acute Supplementation with Cannabidiol Does Not Attenuate Inflammation or Improve Measures of Performance following Strenuous Exercise. Healthcare, 10(6), Article 6. https://doi.org/10.3390/healthcare10061133

Cuñetti, L., Manzo, L., Peyraube, R., Arnaiz, J., Curi, L., & Orihuela, S. (2018). Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay. Transplantation Proceedings, 50(2), 461-464. https://doi.org/10.1016/j.transproceed.2017.12.042

Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R., Sanvito, W. L., Lander, N., & Mechoulam, R. (1980). Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology, 21(3), 175-185.
https://doi.org/10.1159/000137430

Docter, S., Khan, M., Gohal, C., Ravi, B., Bhandari, M., Gandhi, R., & Leroux, T. (2020). Cannabis Use and Sport: A Systematic Review. Sports Health, 12(2), 189-199.
https://doi.org/10.1177/1941738120901670

Fine, P. G., & Rosenfeld, M. J. (2013). The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Medical Journal, 4(4), e0022. https://doi.org/10.5041/RMMJ.10129

Fox, J. L., Scanlan, A. T., Stanton, R., & Sargent, C. (2020). Insufficient Sleep in Young Athletes? Causes, Consequences, and Potential Treatments. Sports Medicine, 50(3), 461-470. https://doi.org/10.1007/s40279-019-01220-8

Gamelin, F.-X., Cuvelier, G., Mendes, A., Aucouturier, J., Berthoin, S., Di Marzo, V., & Heyman, E. (2020). Cannabidiol in sport: Ergogenic or else? Pharmacological Research, 156, 104764. https://doi.org/10.1016/j.phrs.2020.104764

García-Baos, A., Puig-Reyne, X., García-Algar, Ó., & Valverde, O. (2021). Cannabidiol attenuates cognitive deficits and neuroinflammation induced by early alcohol exposure in a mice model. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 141, 111813. https://doi.org/10.1016/j.biopha.2021.111813

Gregorio, D., McLaughlin, R., & Posa, L. (2019). Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain., 160. https://doi.org/10.1097/j.pain.0000000000001386

Hainline, B., Derman, W., Vernec, A., Budgett, R., Deie, M., Dvorak, J., Harle, C., Herring, S. A., McNamee, M., Meeuwisse, W., Moseley, G. L., Omololu, B., Orchard, J., Pipe, A., Pluim, B. M., Raeder, J., Siebert, C., Stewart, M., Stuart, M., … Engebretsen, L. (2017). International Olympic Committee consensus statement on pain management in elite athletes. British Journal of Sports Medicine, 51(17), 1245-1258. https://doi.org/10.1136/bjsports-2017-097884

Hammell, D. C., Zhang, L. P., Ma, F., Abshire, S. M., McIlwrath, S. L., Stinchcomb, A. L., & Westlund, K. N. (2016). Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. European Journal of Pain (London, England), 20(6), 936-948. https://doi.org/10.1002/ejp.818

Hatchett, A., Armstrong, K., Hughes, B., & Parr, B. (2020). The influence cannabidiol on delayed onset of muscle soreness. International Journal of Physical Education, Sports and Health, 7, 89-94.

Haugen, T., Seiler, S., Sandbakk, Ø., & Tønnessen, E. (2019). The Training and Development of Elite Sprint Performance: An Integration of Scientific and Best Practice Literature. Sports Medicine - Open, 5(1), 44. https://doi.org/10.1186/s40798-019-0221-0

Hayakawa, K., Mishima, K., Nozako, M., Hazekawa, M., Irie, K., Fujioka, M., Orito, K., Abe, K., Hasebe, N., Egashira, N., Iwasaki, K., & Fujiwara, M. (2007). Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism. Journal of Neurochemistry, 102(5), 1488-1496. https://doi.org/10.1111/j.1471-4159.2007.04565.x

Higgins, T. R., Greene, D. A., & Baker, M. K. (2017). Effects of Cold Water Immersion and Contrast Water Therapy for Recovery From Team Sport: A Systematic Review and Meta-analysis. Journal of Strength and Conditioning Research, 31(5), 1443-1460. https://doi.org/10.1519/JSC.0000000000001559

Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012). Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology & Therapeutics, 133(1), 79-97. https://doi.org/10.1016/j.pharmthera.2011.09.002

Hill, K. P., Palastro, M. D., Johnson, B., & Ditre, J. W. (2017). Cannabis and Pain: A Clinical Review. Cannabis and Cannabinoid Research, 2(1), 96-104. https://doi.org/10.1089/can.2017.0017

Huestis, M. A., Mazzoni, I., & Rabin, O. (2011). Cannabis in sport: Anti-doping perspective. Sports Medicine (Auckland, N.Z.), 41(11), 949-966. https://doi.org/10.2165/11591430-000000000-00000

Huestis, M. A., Solimini, R., Pichini, S., Pacifici, R., Carlier, J., & Busardò, F. P. (2019). Cannabidiol Adverse Effects and Toxicity. Current Neuropharmacology, 17(10), 974-989. https://doi.org/10.2174/1570159X17666190603171901

Iannotti, F. A., Pagano, E., Moriello, A. S., Alvino, F. G., Sorrentino, N. C., D’Orsi, L., Gazzerro, E., Capasso, R., De Leonibus, E., De Petrocellis, L., & Di Marzo, V. (2019). Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice. British Journal of Pharmacology, 176(10), 1568-1584.
https://doi.org/10.1111/bph.14460

Ignatowska-Jankowska, B., Jankowski, M. M., & Swiergiel, A. H. (2011). Cannabidiol decreases body weight gain in rats: Involvement of CB2 receptors. Neuroscience Letters, 490(1), 82-84. https://doi.org/10.1016/j.neulet.2010.12.031

Isenmann, E., Veit, S., Starke, L., Flenker, U., & Diel, P. (2021). Effects of Cannabidiol Supplementation on Skeletal Muscle Regeneration after Intensive Resistance Training. Nutrients, 13(9), Article 9. https://doi.org/10.3390/nu13093028

Jadoon, K. A., Tan, G. D., & O’Sullivan, S. E. (2017). A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI Insight, 2(12), e93760, 93760. https://doi.org/10.1172/jci.insight.93760

Kasper, A. M., Sparks, S. A., Hooks, M., Skeer, M., Webb, B., Nia, H., Morton, J. P., & Close, G. L. (2020). High Prevalence of Cannabidiol Use Within Male Professional Rugby Union and League Players: A Quest for Pain Relief and Enhanced Recovery. International Journal of Sport Nutrition and Exercise Metabolism, 1-8. https://doi.org/10.1123/ijsnem.2020-0151

Kraft, B., Frickey, N. A., Kaufmann, R. M., Reif, M., Frey, R., Gustorff, B., & Kress, H. G. (2008). Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology, 109(1), 101-110. https://doi.org/10.1097/ALN.0b013e31817881e1

Kramer, A., Sinclair, J., Sharpe, L., & Sarris, J. (2020). Chronic cannabis consumption and physical exercise performance in healthy adults: A systematic review. Journal of Cannabis Research, 2(1), 34. https://doi.org/10.1186/s42238-020-00037-x

Kreher, J. B., & Schwartz, J. B. (2012). Overtraining Syndrome: A Practical Guide. Sports Health: A Multidisciplinary Approach, 4(2), 128-138. https://doi.org/10.1177/1941738111434406

Lattanzi, S., Brigo, F., Trinka, E., Zaccara, G., Cagnetti, C., Del Giovane, C., & Silvestrini, M. (2018). Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis. Drugs, 78(17), 1791-1804. https://doi.org/10.1007/s40265-018-0992-5

Lim, S. Y., Sharan, S., & Woo, S. (2020). Model-Based Analysis of Cannabidiol Dose-Exposure Relationship and Bioavailability. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 40(4), 291-300. https://doi.org/10.1002/phar.2377

Linares, I. M. P., Guimaraes, F. S., Eckeli, A., Crippa, A. C. S., Zuardi, A. W., Souza, J. D. S., Hallak, J. E., & Crippa, J. A. S. (2018). No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Frontiers in Pharmacology, 9, 315. https://doi.org/10.3389/fphar.2018.00315

Lopez, H. L., Cesareo, K. R., Raub, B., Kedia, A. W., Sandrock, J. E., Kerksick, C. M., & Ziegenfuss, T. N. (2020). Effects of Hemp Extract on Markers of Wellness, Stress Resilience, Recovery and Clinical Biomarkers of Safety in Overweight, But Otherwise Healthy Subjects. Journal of Dietary Supplements, 17(5), 561-586. https://doi.org/10.1080/19390211.2020.1765941

Lorenzetti, V., Solowij, N., & Yücel, M. (2016). The Role of Cannabinoids in Neuroanatomic Alterations in Cannabis Users. Biological Psychiatry, 79(7), e17-31. https://doi.org/10.1016/j.biopsych.2015.11.013

Lowin, T., Schneider, M., & Pongratz, G. (2019). Joints for joints: Cannabinoids in the treatment of rheumatoid arthritis. Current Opinion in Rheumatology, 31(3), 271-278. https://doi.org/10.1097/BOR.0000000000000590

Martin, R. C., Gaston, T. E., Thompson, M., Ampah, S. B., Cutter, G., Bebin, E. M., & Szaflarski, J. P. (2019). Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy. Epilepsy & Behavior, 97, 105-110.
https://doi.org/10.1016/j.yebeh.2019.04.044

Martínez-Guardado, I., Rojas-Valverde, D., Gutiérrez-Vargas, R., Ugalde Ramírez, A., Gutiérrez-Vargas, J. C., & Sánchez-Ureña, B. (2020). Intermittent Pneumatic Compression and Cold Water Immersion Effects on Physiological and Perceptual Recovery During Multi-Sports International Championship. Journal of Functional Morphology and Kinesiology, 5(3), Article 3. https://doi.org/10.3390/jfmk5030045

Masataka, N. (2019). Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders. Frontiers in Psychology, 10, 2466. https://doi.org/10.3389/fpsyg.2019.02466

McCartney, D., Benson, M. J., Desbrow, B., Irwin, C., Suraev, A., & McGregor, I. S. (2020). Cannabidiol and Sports Performance: A Narrative Review of Relevant Evidence and Recommendations for Future Research. Sports Medicine - Open, 6(1), 27.
https://doi.org/10.1186/s40798-020-00251-0

McPartland, J. M., Duncan, M., Marzo, V. D., & Pertwee, R. G. (2015). Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. British Journal of Pharmacology, 172(3), 737-753. https://doi.org/10.1111/bph.12944

Medina, J. M., McKeon, P. O., & Hertel, J. (2006). Rating the Levels of Evidence in Sports-Medicine Research. International Journal of Athletic Therapy and Training, 11(5), 38-41. https://doi.org/10.1123/att.11.5.38

Merry, T. L., & Ristow, M. (2016). Do antioxidant supplements interfere with skeletal muscle adaptation to exercise training? The Journal of Physiology, 594(18), 5135-5147. https://doi.org/10.1113/JP270654

Metsios, G. S., Moe, R. H., & Kitas, G. D. (2020). Exercise and inflammation. Best Practice & Research Clinical Rheumatology, 101504. https://doi.org/10.1016/j.berh.2020.101504

Millar, S. A., Stone, N. L., Bellman, Z. D., Yates, A. S., England, T. J., & O’Sullivan, S. E. (2019). A systematic review of cannabidiol dosing in clinical populations. British Journal of Clinical Pharmacology, 85(9), 1888-1900. https://doi.org/10.1111/bcp.14038

Mori, M. A., Meyer, E., Soares, L. M., Milani, H., Guimarães, F. S., & de Oliveira, R. M. W. (2017). Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 75, 94-105. https://doi.org/10.1016/j.pnpbp.2016.11.005

Mukhopadhyay, P., Rajesh, M., Horváth, B., Bátkai., Park O., Tanchian, G., Gao, R. Y., Patel, V., Wink, D. A., Liaudet, L., Haskó, G., Mechoulam, R., Pacher, P., (2011). Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med, 50. https://doi.org/10.1016/j.freeradbiomed.2011.02.021

Murillo-Rodríguez, E., Millán-Aldaco, D., Palomero-Rivero, M., Mechoulam, R., & Drucker-Colín, R. (2006). Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett, 580. https://doi.org/10.1016/j.febslet.2006.04.102

Murillo-Rodríguez, E., Arankowsky-Sandoval, G., Rocha, N. B., Peniche-Amante, R., Veras, A. B., Machado, S., & Budde, H. (2018). Systemic Injections of Cannabidiol Enhance Acetylcholine Levels from Basal Forebrain in Rats. Neurochemical Research, 43(8), 1511-1518. https://doi.org/10.1007/s11064-018-2565-0

Murillo-Rodríguez, E., Budde, H., Veras, A. B., Rocha, N. B., Telles-Correia, D., Monteiro, D., Cid, L., Yamamoto, T., Machado, S., & Torterolo, P. (2020). The Endocannabinoid System May Modulate Sleep Disorders in Aging. Current Neuropharmacology, 18(2), 97-108. https://doi.org/10.2174/1570159X17666190801155922

Myers, A. M., Siegele, P. B., Foss, J. D., Tuma, R. F., & Ward, S. J. (2019). Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice. British Journal of Pharmacology, 176(10), 1552-1567. https://doi.org/10.1111/bph.14147

Neubauer, D., Perković Benedik, M., & Osredkar, D. (2018). Cannabidiol for treatment of refractory childhood epilepsies: Experience from a single tertiary epilepsy center in Slovenia. Epilepsy & Behavior: E&B, 81, 79-85. https://doi.org/10.1016/j.yebeh.2018.02.009

Nichols, J. M., & Kaplan, B. L. F. (2019). Immune Responses Regulated by Cannabidiol. Cannabis and Cannabinoid Research, 5(1), 12-31. https://doi.org/10.1089/can.2018.0073

Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., & Brennan, S. E. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. International Journal of Surgery, 88, 105906.

Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., Emerson, M., Garner, P., Holgate, S. T., Howells, D. W., Karp, N. A., Lazic, S. E., Lidster, K., MacCallum, C. J., Macleod, M., … Würbel, H. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. BMC Veterinary Research, 16(1), 242. https://doi.org/10.1186/s12917-020-02451-y

Peres, F. F., Levin, R., Suiama, M. A., Diana, M. C., Gouvêa, D. A., Almeida, V., Santos, C. M., Lungato, L., Zuardi, A. W., Hallak, J. E. C., Crippa, J. A., Vânia, D., Silva, R. H., & Abílio, V. C. (2016). Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats. Frontiers in Pharmacology, 7, 343. https://doi.org/10.3389/fphar.2016.00343

Pinto, J. V., Saraf, G., Frysch, C., Vigo, D., Keramatian, K., Chakrabarty, T., Lam, R. W., Kauer-Sant’Anna, M., & Yatham, L. N. (2020). Cannabidiol as a Treatment for Mood Disorders: A Systematic Review. The Canadian Journal of Psychiatry, 65(4), 213-227. https://doi.org/10.1177/0706743719895195

Reillo, M. R. (2019). Cannabidiol (CBD) in the Management of Sports-Related Traumatic Brain Injury: Research and Efficacy. Sports Injuries & Medicine, 3(2). https://doi.org/10.29011/2576-9596.100058

Rojas-Valverde, D. (2021). Potential role of cannabidiol (CBD) on sport recovery: A narrative review. Frontiers in Physiology, 12. https://doi.org/10.3389/fphys.2021.722550

Rojas-Valverde, D., Gutiérrez-Vargas, R., Rodríguez-Montero, A., Pereira, L. A., Loturco, I., & Martín-Rodríguez, S. (2018). Reduced muscle contractile function in elite young soccer players after a short-congested fixture period. Proceedings of the Institution of Mechanical Engineers, Part P: Journal of Sports Engineering and Technology, 175433711881795. https://doi.org/10.1177/1754337118817957

Rojas-Valverde, D., Montoya-Rodríguez, J., Azofeifa-Mora, C., & Sanchez-Urena, B. (2020). Effectiveness of beetroot juice derived nitrates supplementation on fatigue resistance during repeated-sprints: A systematic review. Critical Reviews in Food Science and Nutrition, 1-12. https://doi.org/10.1080/10408398.2020.1798351

Rojas-Valverde, D., Sánchez-Ureña, B., Crowe, J., Timón, R., & Olcina, G. J. (2020). Exertional Rhabdomyolysis and Acute Kidney Injury in Endurance Sports: A Systematic Review. European Journal of Sport Science, 0(ja), 1-28. https://doi.org/10.1080/17461391.2020.1746837

Rudroff, T., & Sosnoff, J. (2018). Cannabidiol to Improve Mobility in People with Multiple Sclerosis. Frontiers in Neurology, 9. https://doi.org/10.3389/fneur.2018.00183

Sahinovic, A., Irwin, C., Doohan, P. T., Kevin, R. C., Cox, A. J., Lau, N. S., Desbrow, B., Johnson, N. A., Sabag, A., Hislop, M., Haber, P. S., McGregor, I. S., & McCartney, D. (2022). Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial. Sports Medicine - Open, 8(1), 27. https://doi.org/10.1186/s40798-022-00417-y

Santiago, A. N., Mori, M. A., Guimaraes, F. S., Milani, H., & Weffort de Oliveira, R. M. (2019). Effects of Cannabidiol on Diabetes Outcomes and Chronic Cerebral Hypoperfusion Comorbidities in Middle-Aged Rats. Neurotoxicity Research, 35(2), 463-474.
https://doi.org/10.1007/s12640-018-9972-5

Santos de Alencar, S., Crippa, J. A. S., Brito, M. C. M., Pimentel, Â. V., Cecilio Hallak, J. E., & Tumas, V. (2021). A single oral dose of cannabidiol did not reduce upper limb tremor in patients with essential tremor. Parkinsonism & Related Disorders, 83, 37-40. https://doi.org/10.1016/j.parkreldis.2021.01.001

Schiavon, A. P., Soares, L. M., Bonato, J. M., Milani, H., Guimarães, F. S., & Weffort de Oliveira, R. M. (2014). Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice. Neurotoxicity Research, 26(4), 307-316. https://doi.org/10.1007/s12640-014-9457-0

Schleicher, E. M., Ott, F. W., Mueller, M., Silcher, B., Sichler, M. E., Loew, M. J., Wagner, J. M., & Bouter, Y. (2019). Prolonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor Performance and Anxiety in C57BL/6J Mice. Frontiers in Behavioral Neuroscience, 13, 94. https://doi.org/10.3389/fnbeh.2019.00094

Shannon, S., Lewis, N., Lee, H., & Hughes, S. (2019). Cannabidiol in Anxiety and Sleep: A Large Case Series. The Permanente Journal, 23. https://doi.org/10.7812/TPP/18-041

Shannon, S., & Opila-Lehman, J. (2016). Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report. The Permanente Journal, 20(4), 16-005. https://doi.org/10.7812/TPP/16-005

Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., Kristjansson, E., & Henry, D. A. (2017). AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 358, j4008. https://doi.org/10.1136/bmj.j4008

Sholler, D. J., Schoene, L., & Spindle, T. R. (2020). Therapeutic Efficacy of Cannabidiol (CBD): A Review of the Evidence from Clinical Trials and Human Laboratory Studies. Current Addiction Reports, 7(3), 405-412. https://doi.org/10.1007/s40429-020-00326-8

Singh, J., & Neary, J. P. (2020). Neuroprotection Following Concussion: The Potential Role for Cannabidiol. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques, 47(3), 289-300. https://doi.org/10.1017/cjn.2020.23

Souza, M. T. de, Silva, M. D. da, & Carvalho, R. de. (2010). Integrative review: What is it? How to do it? Einstein (São Paulo), 8, 102-106.

Stanley, C. P., Hind, W. H., & O’Sullivan, S. E. (2013). Is the cardiovascular system a therapeutic target for cannabidiol? British Journal of Clinical Pharmacology, 75(2), 313-322. https://doi.org/10.1111/j.1365-2125.2012.04351.x

Stout, S. M., & Cimino, N. M. (2014). Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: A systematic review. Drug Metabolism Reviews, 46(1), 86-95. https://doi.org/10.3109/03602532.2013.849268

Tantimonaco, M., Ceci, R., Sabatini, S., Catani, M. V., Rossi, A., Gasperi, V., & Maccarrone, M. (2014). Physical activity and the endocannabinoid system: An overview. Cellular and Molecular Life Sciences, 71(14), 2681-2698. https://doi.org/10.1007/s00018-014-1575-6

Thomas, D. T., Erdman, K. A., & Burke, L. M. (2016). Position of the Academy of Nutrition and Dietetics, Dietitians of Canada, and the American College of Sports Medicine: Nutrition and Athletic Performance. Journal of the Academy of Nutrition and Dietetics, 116(3), 501-528. https://doi.org/10.1016/j.jand.2015.12.006

Toronto, C. E., & Remington, R. (Eds.). (2020). A Step-by-Step Guide to Conducting an Integrative Review. Springer International Publishing. https://doi.org/10.1007/978-3-030-37504-1

VanDolah, H. J., Bauer, B. A., & Mauck, K. F. (2019). Clinicians’ Guide to Cannabidiol and Hemp Oils. Mayo Clinic Proceedings, 94(9), 1840-1851. https://doi.org/10.1016/j.mayocp.2019.01.003

Verma, K., Singh, D., & Srivastava, A. (2022). The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic Review. Cureus, 14(8), e28425. https://doi.org/10.7759/cureus.28425

Vuolo, F., Abreu, S. C., Michels, M., Xisto, D. G., Blanco, N. G., Hallak, J. E., Zuardi, A. W., Crippa, J. A., Reis, C., Bahl, M., Pizzichinni, E., Maurici, R., Pizzichinni, M. M. M., Rocco, P. R. M., & Dal-Pizzol, F. (2019). Cannabidiol reduces airway inflammation and fibrosis in experimental allergic asthma. European Journal of Pharmacology, 843, 251-259. https://doi.org/10.1016/j.ejphar.2018.11.029

Vuolo, F., Petronilho, F., Sonai, B., Ritter, C., Hallak, J. E. C., Zuardi, A. W., Crippa, J. A., & Dal-Pizzol, F. (2015). Evaluation of Serum Cytokines Levels and the Role of Cannabidiol Treatment in Animal Model of Asthma. Mediators of Inflammation, 2015, 538670. https://doi.org/10.1155/2015/538670

Wang, Y., Mukhopadhyay, P., Cao, Z., Wang, H., Feng, D., Haskó, G., Mechoulam, R., Gao, B., & Pacher, P. (2017). Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury. Scientific Reports, 7(1), 12064. https://doi.org/10.1038/s41598-017-10924-8

Ware, M., Jensen, D., Barrette, A., Vernec, A., & Derman, W. (2018). Cannabis and the health and performance of the elite athlete. Clin J Sport Med, 28.

Wheal, A. J., Cipriano, M., Fowler, C. J., Randall, M. D., & O’Sullivan, S. E. (2014). Cannabidiol improves vasorelaxation in Zucker diabetic fatty rats through cyclooxygenase activation. The Journal of Pharmacology and Experimental Therapeutics, 351(2), 457-466. https://doi.org/10.1124/jpet.114.217125

Whiting, P. F., Wolff, R. F., Deshpande, S., Nisio, M. D., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., Schmidlkofer, S., Westwood, M., & Kleijnen, J. (2015). Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA, 313(24), 2456-2473. https://doi.org/10.1001/jama.2015.6358

Whittemore, R., & Knafl, K. (2005). The integrative review: Updated methodology. Journal of Advanced Nursing, 52(5), 546-553. https://doi.org/10.1111/j.1365-2648.2005.03621.x

WHO. (2017). Cannabidiol (CBD): World Health Organisation expert committe on drug dependence. Thyrty-Ninth Meeting. https://www.who.int/medicines/access/controlled-substances/5.2_CBD.pdf

Yeager, M. P., Pioli, P. A., & Guyre, P. M. (2010). Cortisol Exerts Bi-Phasic Regulation of Inflammation in Humans. Dose-Response, 9(3), 332-347. https://doi.org/10.2203/dose-response.10-013.Yeager

Zarrabi, A. J., Frediani, J. K., & Levy, J. M. (2020). The State of Cannabis Research Legislation in 2020. The New England Journal of Medicine, 382(20), 1876-1877. https://doi.org/10.1056/NEJMp2003095

Zieba, J., Sinclair, D., Sebree, T., Bonn-Miller, M., Gutterman, D., Siegel, S., & Karl, T. (2019). Cannabidiol (CBD) reduces anxiety-related behavior in mice via an FMRP-independent mechanism. Pharmacology Biochemistry and Behavior, 181, 93-100. https://doi.org/10.1016/j.pbb.2019.05.002

Zuardi, A., Cosme, R., Graeff, F., & Guimaraes, F. (1993). Effects of Ipsapirone and Cannabidiol on Human Experimental Anxiety. Journal of Psychopharmacology, 7(1), 82-88. https://doi.org/10.1177/026988119300700112

Zuardi, A., Crippa, J., Dursun, S., Morais, S., Vilela, J., Sanches, R., & Hallak, J. (2010). Cannabidiol was ineffective for manic episode of bipolar affective disorder. Journal of Psychopharmacology (Oxford, England), 24(1), 135-137. https://doi.org/10.1177/0269881108096521

Zuardi, A. W., Guimarães, F. S., & Moreira, A. C. (1993). Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas, 26(2), 213-217.

Zurier, R. B., & Burstein, S. H. (2016). Cannabinoids, inflammation, and fibrosis. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 30(11), 3682-3689. https://doi.org/10.1096/fj.201600646R

Acknowledgments: None reported by authors.

Contribution statement: Author 1 (Conceptualization; Formal analysis; Investigation; Methodology; Writing - original draft), Author 2 (Data curation; Investigation; Methodology; Software; Visualization; Writing - original draft), Author 3, 4 and 5 (Data curation; Project administration; Resources; Supervision; Visualization; Writing - review & editing).

Financiación / Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicto de intereses / Conflicts of Interest: The authors of the present study declare no conflicts of interest when writing the manuscript.

---

1. Recibido: 14/06/2024 Aceptado: 14/08/2025

   1 Universidad Nacional, Escuela Ciencias del Movimiento Humano y Calidad de Vida (CIEMHCAVI), Núcleo de Estudios en Alto Rendimiento y Salud (NARS), Centro de Investigación, Desarrollo e Innovación en Salud y Deporte (CIDISAD), Heredia, Costa Rica. cavg03@gmail.com 0009-0004-1397-8697

2. 2 Universidad de Murcia, Facultad de Ciencias del Deporte, Grupo de Investigación BioVetMed & SportSci, Murcia, España. carlosdavid.gomez@um.es 0000-0002-4084-8124

3. 3 Universidad Nacional, Escuela Ciencias del Movimiento Humano y Calidad de Vida (CIEMHCAVI), Núcleo de Estudios en Alto Rendimiento y Salud (NARS), Programa de Ciencias del Ejercicio y la Salud (PROCESA), Heredia, Costa Rica. braulio.sanchez.urena@una.ac.cr 0000-0001-8791-6836

4. 4 Universidad Nacional, Escuela Ciencias del Movimiento Humano y Calidad de Vida (CIEMHCAVI), Núcleo de Estudios en Alto Rendimiento y Salud (NARS), Programa de Ciencias del Ejercicio y la Salud (PROCESA), Heredia, Costa Rica. cristian.azofeifa.mora@una.cr 0000-0001-8085-9584

5. 5 Universidad Nacional, Escuela Ciencias del Movimiento Humano y Calidad de Vida (CIEMHCAVI), Núcleo de Estudios en Alto Rendimiento y Salud (NARS), Centro de Investigación, Desarrollo e Innovación en Salud y Deporte (CIDISAD), Heredia, Costa Rica. drojasv@una.cr 0000-0002-0717-8827

Escuela de Ciencias del Movimiento Humano y Calidad de Vida
Benjamín Nuñez Campus, Universidad Nacional, Lagunilla, Heredia, Costa Rica
PO Box: 86-3000. Heredia, Costa Rica
Phone: (506) 2562-6980
E-mail revistamhsalud@una.ac.cr